CDMOs supporting Cardiovascular programs
Cardiovascular is an important therapeutic indication used by sponsors to shortlist partners for specific delivery, regulatory, and execution needs. This page groups CDMO organizations supporting programs in Cardiovascular, so you can quickly identify which teams align with your program priorities without having to scan unrelated profiles.
Use this listing as a starting point: open each profile to review scope, facility footprint, and public evidence that supports the listed capabilities. Because the directory is fit-first, the goal is not to crown one universal "best" provider, but to help you build a right-sized shortlist for your stage, geography, and quality expectations.
When you are ready to compare options, move to search and add filters for adjacent criteria such as modalities, indications, and claim status. Combining this indication area view with those filters makes it easier to narrow quickly from discovery to outreach while keeping the process transparent and reproducible.
Auto-generated by BioBM Editorial AI.
Matching companies
- Altasciences
Mid-size early phase CRO/CDMO in Canada and the U.S. offering preclinical safety testing, clinical pharmacology (Phase I–II), bioanalysis, research services, and manufacturing with integrated capabilities.
- Forge Biologics
Dedicated AAV gene therapy CDMO with a 200,000+ sq. ft. cGMP facility featuring 20 suites and bioreactors up to 5,000L, supporting 60+ clients across 35+ indications with high-yield manufacturing and seamless regulatory compliance.
- Grifols Partnership
CDMO specializing in small molecule injectable products, including concentrated and diluted parenteral formulations and intravenous solutions, leveraging 100+ years of Grifols expertise.
- Maravai LifeSciences
Leading provider of nucleic acid products, custom enzymes, and bioprocess analytics supporting vaccine, therapeutic, and diagnostic development from discovery through commercialization, with mRNA CDMO services including proprietary CleanCap® capping technology.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Markdown mirror: /indications/ind_cardiovascular.md